Design Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Design Therapeutics, Inc. (DSGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 167.58 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-03
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 34.67K shares, a 88.29% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 132.92K shares, a 1479.15% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 59.78K shares, a 87.96% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 67.81K shares, a 31.58% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 432.00K shares, a 57.43% decline from fiscal 2024.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 1.01M shares, a 39.94% decline from fiscal 2023.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 1.69M shares, a 822.33% increase from fiscal 2022.
- Design Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 183.21K shares, a 41.64% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 34.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 167.58K shares 10-Q · filed 2026-08-03 | 227.37K shares derived: sum of 3 quarters · filed 2026-08-03 | 295.17K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 132.92K shares 10-Q · filed 2026-04-28 | 192.70K shares derived: sum of 2 quarters · filed 2026-04-28 | 260.51K shares derived: sum of 3 quarters · filed 2026-04-28 | 556.50K shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 59.78K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 127.59K shares derived: sum of 2 quarters · filed 2026-03-09 | 423.58K shares derived: sum of 3 quarters · filed 2026-03-09 | 432.00K shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 67.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 363.80K shares derived: sum of 2 quarters · filed 2025-11-05 | 372.21K shares 10-Q · filed 2025-11-05 | 868.83K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 295.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 304.41K shares 10-Q · filed 2025-08-07 | 801.02K shares derived: sum of 3 quarters · filed 2025-08-07 | 852.55K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 8.42K shares 10-Q · filed 2025-05-07 | 505.03K shares derived: sum of 2 quarters · filed 2025-05-07 | 556.56K shares derived: sum of 3 quarters · filed 2025-05-07 | 695.23K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 496.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 548.14K shares derived: sum of 2 quarters · filed 2025-03-10 | 686.81K shares derived: sum of 3 quarters · filed 2025-03-10 | 1.01M shares 10-K · filed 2025-03-10 |
| 2024-09-30 | 51.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 190.20K shares derived: sum of 2 quarters · filed 2024-11-07 | 518.28K shares 10-Q · filed 2024-11-07 | 1.03M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 138.67K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 466.75K shares 10-Q · filed 2024-08-05 | 979.96K shares derived: sum of 3 quarters · filed 2024-08-05 | 2.02M shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 328.08K shares 10-Q · filed 2024-05-08 | 841.29K shares derived: sum of 2 quarters · filed 2024-05-08 | 1.88M shares derived: sum of 3 quarters · filed 2024-05-08 | 1.96M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 513.21K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 1.55M shares derived: sum of 2 quarters · filed 2024-03-19 | 1.63M shares derived: sum of 3 quarters · filed 2024-03-19 | 1.69M shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 1.04M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 1.12M shares derived: sum of 2 quarters · filed 2023-11-13 | 1.18M shares 10-Q · filed 2023-11-13 | 1.18M shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-06-30 | 79.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 139.91K shares 10-Q · filed 2023-08-14 | 141.94K shares derived: sum of 3 quarters · filed 2024-03-19 | 313.13K shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2023-03-31 | 60.85K shares 10-Q · filed 2023-05-09 | 62.89K shares derived: sum of 2 quarters · filed 2024-03-19 | 234.07K shares derived: sum of 3 quarters · filed 2024-03-19 | 234.07K shares derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-12-31 | 2.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 173.21K shares derived: sum of 2 quarters · filed 2024-03-19 | 173.21K shares derived: sum of 3 quarters · filed 2024-03-19 | 183.21K shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 171.18K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 171.18K shares derived: sum of 2 quarters · filed 2022-11-03 | 181.18K shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 10.00K shares 10-Q · filed 2022-08-08 | ||
| 2022-03-31 | 10.00K shares 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 313.91K shares 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |